A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
Hutchmed
Hutchmed
Gradalis, Inc.
PharmaMar
Novartis
Vanquish Oncology, Inc.
Eli Lilly and Company
Mateon Therapeutics
NantCell, Inc.
Novartis
INSYS Therapeutics Inc
Novartis